Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cullinan Therapeutics, Inc. (CGEM)
USD17.77
-0.01 (-0.03%)
US NASDAQ Healthcare Medical - Pharmaceuticals
Address
One Main Street 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
Nadim Ahmed
Website
cullinantherapeutics.com
IPO
2021-01-08
CIK 1789972 ISIN US2300311063
Description
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD17.77
-0.01 (-0.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.01
Float Shares
43.34M
Free Float %
70.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.80% | +13.58% | -0.94% | +20.36% | +104.73% | +42.22% | +91.17% | +54.78% | -50.70% | -50.79% | -50.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
17.77
Low
26.00
+46.4%
Consensus
31.14
+75.3%
Median
30.00
+68.9%
High
38.00
+113.9%
DCF (Unlevered)
1.44
-91.9%
DCF (Levered)
1.45
-91.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 11 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
30.00
+68.9%
|
| Last Quarter | 3 |
31.33
+76.4%
|
| Last Year | 9 |
31.00
+74.5%
|
| All Time | 15 |
30.20
+70.0%
|
Quality scores
Altman Z-Score
11.80
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%-19.6% Q1'26: -2.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%-721.0% Q1'26: -1,288.5% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+9.8% Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
Dec 2029 7 Rev. Ana. 4 EPS Ana. |
Dec 2030 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 4.50M (-100.0%)
|
18.94M
est: 18.91M (+0.2%)
|
—
est: 1.67M (-100.0%)
|
—
est: 5.18M (-100.0%)
|
22.32M
5.80M – 38.85M
+330.9% YoY
|
48.28M
8.95M – 81.89M
+116.3% YoY
|
33.97M
7.54M – 58.37M
-29.6% YoY
|
69.74M
15.48M – 119.82M
+105.3% YoY
|
228.55M
50.74M – 392.69M
+227.7% YoY
|
| EBITDA |
-60.27M
est: 2.70M (-2,332.3%)
|
-67.90M
est: 11.35M (-698.3%)
|
-167.15M
est: 1.00M (-16,815.2%)
|
-241.34M
est: 3.11M (-7,865.5%)
|
13.39M
3.48M – 23.31M
+330.9% YoY
|
28.97M
5.37M – 49.13M
+116.3% YoY
|
20.38M
4.53M – 35.02M
-29.6% YoY
|
41.84M
9.29M – 71.89M
+105.3% YoY
|
137.13M
30.44M – 235.61M
+227.7% YoY
|
| EBIT |
-60.34M
est: 2.70M (-2,334.6%)
|
-67.95M
est: 11.35M (-698.8%)
|
-167.46M
est: 1.00M (-16,845.8%)
|
-241.65M
est: 3.11M (-7,875.5%)
|
13.39M
3.48M – 23.31M
+330.9% YoY
|
28.97M
5.37M – 49.13M
+116.3% YoY
|
20.38M
4.53M – 35.02M
-29.6% YoY
|
41.84M
9.29M – 71.89M
+105.3% YoY
|
137.13M
30.44M – 235.61M
+227.7% YoY
|
| Net Income |
-51.80M
est: -109.69M (+52.8%)
|
-65.57M
est: -68.69M (+4.5%)
|
-167.38M
est: -182.45M (+8.3%)
|
-219.88M
est: -221.04M (+0.5%)
|
-206.75M
-216.74M – -130.52M
+6.5% YoY
|
-139.64M
-162.13M – -117.15M
+32.5% YoY
|
-171.02M
-216.75M – -125.29M
-22.5% YoY
|
-170.95M
-330.55M – 1.95M
+0.0% YoY
|
-96.40M
-186.40M – 1.10M
+43.6% YoY
|
| SGA |
17.12M
est: 4.98M (+243.5%)
|
29.15M
est: 20.95M (+39.1%)
|
53.71M
est: 1.85M (+2,809.2%)
|
54.25M
est: 5.74M (+845.4%)
|
24.72M
6.42M – 43.03M
+330.9% YoY
|
53.48M
9.91M – 90.71M
+116.3% YoY
|
37.63M
8.35M – 64.66M
-29.6% YoY
|
77.25M
17.15M – 132.73M
+105.3% YoY
|
253.17M
56.20M – 434.99M
+227.7% YoY
|
| EPS |
-1.19
est: -2.04 (+41.7%)
|
-1.48
est: -1.28 (-15.9%)
|
-3.11
est: -2.99 (-4.0%)
|
-3.72
est: -3.56 (-4.4%)
|
-3.03
-3.67 – -2.21
+15.0% YoY
|
-2.37
-2.75 – -1.98
+21.8% YoY
|
-2.86
-3.67 – -2.12
-20.8% YoY
|
-2.90
-5.60 – 0.03
-1.1% YoY
|
-1.63
-3.16 – 0.02
+43.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | BTIG | Buy | Buy | Maintain |
| 2026-04-28 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-175.75M
OE per share TTM
-2.98
Owner's Yield
-20.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
77.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
35
Total invested
155.41M
Insider transactions (90d)
1
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Morana Jovan-Embiricos | 6.28M | 14.30% | 252.9K | 6.03M | 252.9K | 6.03M | IN | British Virgin Islands | 2022-02-10 | ↗ |
| 2 | BVF Inc. | 5.37M | 12.30% | — | — | — | 5.37M | CO | — | 2022-02-14 | ↗ |
| 3 | BVF Partners L.P. | 5.37M | 12.30% | — | — | — | 5.37M | IA, PN | — | 2022-02-14 | ↗ |
| 4 | Mark N. Lampert | 5.37M | 12.30% | — | — | — | 5.37M | IN | — | 2022-02-14 | ↗ |
| 5 | BVF GP HOLDINGS LLC | 4.98M | 11.40% | — | — | — | 4.98M | OO | — | 2022-02-14 | ↗ |
| 6 | (1) BlackRock, Inc. | 4.34M | 7.50% | — | 4.26M | 4.34M | — | HC | Delaware | 2024-11-08 | ↗ |
| 7 | Blue Owl Capital Holdings LP | 3.42M | 7.99% | 3.42M | — | 3.42M | — | PN | Delaware | 2024-02-14 | ↗ |
| 8 | Deerfield Management Company, L.P. | 3.28M | 5.71% | — | 3.28M | — | — | PN | Delaware | 2024-04-24 | ↗ |
| 9 | Deerfield Mgmt, L.P. | 3.28M | 5.71% | — | 3.28M | — | — | PN | Delaware | 2024-04-24 | ↗ |
| 10 | Deerfield Partners, L.P. | 3.28M | 5.71% | — | 3.28M | — | — | PN | Delaware | 2024-04-24 | ↗ |
| 11 | James E. Flynn | 3.28M | 5.71% | — | 3.28M | — | — | IN | United States | 2024-04-24 | ↗ |
| 12 | F2 Vision Management Sarl | 2.91M | 6.70% | — | 2.91M | — | 2.91M | CO | British Virgin Islands | 2022-02-10 | ↗ |
| 13 | F2 Vision SCS | 2.91M | 6.70% | — | 2.91M | — | 2.91M | PN | British Virgin Islands | 2022-02-10 | ↗ |
| 14 | BVF I GP LLC | 2.79M | 6.40% | — | — | — | 2.79M | OO | — | 2022-02-14 | ↗ |
| 15 | Biotechnology Value Fund, L.P. | 2.79M | 6.40% | — | — | — | 2.79M | PN | — | 2022-02-14 | ↗ |
| 16 | CHI Advisors LLC | 2.48M | 5.67% | 2.48M | — | — | — | IA | Delaware | 2022-02-11 | ↗ |
| 17 | The Vanguard Group - 23-1945930 | 2.37M | 5.42% | — | — | — | 33.8K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 18 | BVF II GP LLC | 2.19M | 5.00% | — | — | — | 2.19M | OO | — | 2022-02-14 | ↗ |
| 19 | Biotechnology Value Fund II, L.P. | 2.19M | 5.00% | — | — | — | 2.19M | PN | — | 2022-02-14 | ↗ |
| 20 | Globeways Holdings Ltd. | 2.10M | 4.80% | — | 2.10M | — | 2.10M | PN | British Virgin Islands | 2022-02-10 | ↗ |
| 21 | Globeways Holdings II Ltd. | 1.01M | 2.30% | — | 1.01M | — | 1.01M | PN | British Virgin Islands | 2022-02-10 | ↗ |
| 22 | F2 Bioscience I 2017 Ltd. | 639.3K | 1.50% | — | 639.3K | — | 639.3K | PN | British Virgin Islands | 2022-02-10 | ↗ |
| 23 | F2-TPO Investments, LLC | 622.2K | 1.40% | — | 622.2K | — | 622.2K | OO | British Virgin Islands | 2022-02-10 | ↗ |
| 24 | F2 MG Ltd. | 325.3K | 0.70% | — | 325.3K | — | 325.3K | PN | British Virgin Islands | 2022-02-10 | ↗ |
| 25 | BVF Partners OS Ltd. | 301.7K | 1.00% | — | — | — | 301.7K | CO | — | 2022-02-14 | ↗ |
| 26 | Biotechnology Value Trading Fund OS LP | 301.7K | 1.00% | — | — | — | 301.7K | PN | — | 2022-02-14 | ↗ |
| 27 | F2 MC, LLC | 214.8K | 0.50% | — | 214.8K | — | 214.8K | OO | British Virgin Islands | 2022-02-10 | ↗ |
| 28 | F2 GC, LLC | 104.8K | 0.20% | — | 104.8K | — | 104.8K | OO | British Virgin Islands | 2022-02-10 | ↗ |
| 29 | F2 Bio TD, LLC | 71.6K | 0.20% | — | 71.6K | — | 71.6K | OO | British Virgin Islands | 2022-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
35
-121 vs prev Q
New positions
8
Closed positions
125
Increased
20
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 310.0K +310.0K (+100.0%) | 3.21B +3.2B (+100.0%) | 0.53% +0.525 pp | 0.95% +0.947 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 2 | LYNX1 CAPITAL MANAGEMENT LP | 8.96M +3.2M (+55.5%) | 92.77M +58.6M (+171.3%) | 15.19% +5.418 pp | 18.78% +11.820 pp | USD9.16 +13.0% | 7 qtrs — |
| 3 | BIOIMPACT CAPITAL LLC | 7.65M +— (+0.0%) | 79.16M +33.8M (+74.5%) | 12.96% +0.000 pp | 9.06% +1.633 pp | USD41.67 -75.2% | 20 qtrs — |
| 4 | BVF INC/IL | 5.75M +— (+0.0%) | 59.52M +25.4M (+74.5%) | 9.74% +0.000 pp | 2.00% +0.621 pp | USD17.02 -39.2% | 20 qtrs — |
| 5 | BLACKROCK, INC. | 4.40M +230.3K (+5.5%) | 45.54M +20.8M (+84.2%) | 7.46% +0.390 pp | 0.00% +0.000 pp | USD16.37 -36.8% | 6 qtrs — |
| 6 | VANGUARD GROUP INC | 3.30M +355.2K (+12.1%) | 34.14M +16.7M (+95.6%) | 5.59% +0.602 pp | 0.00% +0.000 pp | USD21.32 -51.5% | 20 qtrs — |
| 7 | KYNAM CAPITAL MANAGEMENT, LP | 3.11M +812.0K (+35.3%) | 32.23M +18.6M (+136.1%) | 5.28% +1.376 pp | 2.06% +1.043 pp | USD9.85 +5.1% | 5 qtrs — |
| 8 | BLUE OWL CAPITAL HOLDINGS LP | 2.35M -160.0K (-6.4%) | 24.33M +9.4M (+63.4%) | 3.98% -0.271 pp | 1.82% -2.802 pp | USD10.19 +1.6% | 9 qtrs — |
| 9 | STATE STREET CORP | 2.20M +520.0K (+31.0%) | 22.74M +12.8M (+128.6%) | 3.72% +0.881 pp | 0.00% +0.000 pp | USD15.47 -33.1% | 20 qtrs — |
| 10 | AFFINITY ASSET ADVISORS, LLC | 1.93M +1.7M (+632.4%) | 20.00M +18.4M (+1,178.2%) | 3.27% +2.827 pp | 1.14% +1.003 pp | USD10.35 +0.0% | 9 qtrs — |
| 11 | RTW INVESTMENTS, LP | 1.71M +— (+0.0%) | 17.66M +7.5M (+74.5%) | 2.89% +0.000 pp | 0.18% +0.052 pp | USD16.73 -38.1% | 7 qtrs — |
| 12 | VR ADVISER, LLC | 1.38M +— (+0.0%) | 14.28M +6.1M (+74.5%) | 2.34% +0.000 pp | 0.71% +0.245 pp | USD16.73 -38.1% | 7 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.30M +6.9K (+0.5%) | 13.48M +5.8M (+75.5%) | 2.21% +0.012 pp | 0.00% +0.000 pp | USD19.65 -47.3% | 20 qtrs — |
| 14 | BOOTHBAY FUND MANAGEMENT, LLC | 1.24M +1.2M (+100.0%) | 12.80M +12.8M (+100.0%) | 2.10% +2.096 pp | 0.19% +0.191 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 15 | SIREN, L.L.C. | 1.19M +— (+0.0%) | 12.35M +5.3M (+74.5%) | 2.02% +0.000 pp | 0.37% +0.092 pp | USD16.74 -38.2% | 6 qtrs — |
| 16 | NEXTECH INVEST, LTD. | 1.14M +— (+0.0%) | 11.81M +5.0M (+74.5%) | 1.93% +0.000 pp | 1.14% +0.112 pp | USD7.57 +36.7% | 4 qtrs — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 848.8K -335.1K (-28.3%) | 8.78M +1.8M (+25.1%) | 1.44% -0.568 pp | 0.00% +0.000 pp | USD12.21 -15.2% | 14 qtrs — |
| 18 | MORGAN STANLEY | 766.9K +366.8K (+91.7%) | 7.94M +5.6M (+234.5%) | 1.30% +0.622 pp | 0.00% +0.000 pp | USD10.08 +2.7% | 20 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 721.9K -262.1K (-26.6%) | 7.47M +1.6M (+28.0%) | 1.22% -0.444 pp | 0.00% +0.000 pp | USD12.79 -19.1% | 20 qtrs — |
| 20 | GREAT POINT PARTNERS LLC | 634.0K +634.0K (+100.0%) | 6.56M +6.6M (+100.0%) | 1.07% +1.074 pp | 2.13% +2.128 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 21 | RENAISSANCE TECHNOLOGIES LLC | 631.7K +102.3K (+19.3%) | 6.54M +3.4M (+108.3%) | 1.07% +0.173 pp | 0.01% +0.006 pp | USD9.33 +10.9% | 19 qtrs — |
| 22 | TWIN FOCUS CAPITAL PARTNERS, LLC | 595.5K +— (+0.0%) | 6.16M +2.6M (+74.5%) | 1.01% +0.000 pp | 0.71% +0.262 pp | USD16.73 -38.1% | 7 qtrs — |
| 23 | DEUTSCHE BANK AG\ | 586.6K +14.9K (+2.6%) | 6.07M +2.7M (+79.1%) | 0.99% +0.025 pp | 0.00% +0.001 pp | USD10.52 -1.6% | 20 qtrs — |
| 24 | NUVEEN, LLC | 579.1K +363.5K (+168.6%) | 5.99M +4.7M (+368.8%) | 0.98% +0.616 pp | 0.00% +0.001 pp | USD9.22 +12.3% | 4 qtrs — |
| 25 | TWO SIGMA INVESTMENTS, LP | 470.5K +410.9K (+688.5%) | 4.87M +4.5M (+1,276.3%) | 0.80% +0.696 pp | 0.01% +0.006 pp | USD9.79 +5.7% | 9 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 436.3K +33.6K (+8.4%) | 4.52M +2.1M (+89.1%) | 0.74% +0.057 pp | 0.00% +0.000 pp | USD19.35 -46.5% | 20 qtrs — |
| 27 | NORTHERN TRUST CORP | 421.6K -25.6K (-5.7%) | 4.36M +1.7M (+64.5%) | 0.71% -0.043 pp | 0.00% +0.000 pp | USD21.82 -52.6% | 20 qtrs — |
| 28 | MARSHALL WACE, LLP | 414.4K +118.9K (+40.3%) | 4.29M +2.5M (+144.8%) | 0.70% +0.202 pp | 0.00% +0.002 pp | USD14.17 -27.0% | 11 qtrs — |
| 29 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 386.2K -2.5M (-86.8%) | 4.00M -13.4M (-77.0%) | 0.65% -4.305 pp | 0.05% -0.214 pp | USD15.74 -34.2% | 8 qtrs — |
| 30 | TREXQUANT INVESTMENT LP | 381.5K +193.9K (+103.4%) | 3.95M +2.8M (+254.9%) | 0.65% +0.329 pp | 0.04% +0.024 pp | USD8.68 +19.2% | 4 qtrs — |
| 31 | JUMP FINANCIAL, LLC | 364.9K +170.4K (+87.6%) | 3.78M +2.6M (+227.4%) | 0.62% +0.289 pp | 0.05% +0.033 pp | USD7.99 +29.5% | 2 qtrs — |
| 32 | MILLENNIUM MANAGEMENT LLC | 362.5K -188.0K (-34.1%) | 3.75M +487.5K (+14.9%) | 0.61% -0.319 pp | 0.00% +0.000 pp | USD15.73 -34.2% | 6 qtrs — |
| 33 | POINT72 ASSET MANAGEMENT, L.P. | 360.2K +360.2K (+100.0%) | 3.73M +3.7M (+100.0%) | 0.61% +0.610 pp | 0.00% +0.004 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 34 | BANK OF AMERICA CORP /DE/ | 346.3K -210.9K (-37.8%) | 3.58M +280.1K (+8.5%) | 0.59% -0.357 pp | 0.00% +0.000 pp | USD9.22 +12.3% | 20 qtrs — |
| 35 | SCHRODER INVESTMENT MANAGEMENT GROUP | 343.7K +343.7K (+100.0%) | 3.41M +3.4M (+100.0%) | 0.58% +0.582 pp | 0.00% +0.003 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 36 | AQR CAPITAL MANAGEMENT LLC | 281.5K +83.6K (+42.2%) | 2.91M +1.7M (+148.2%) | 0.48% +0.142 pp | 0.00% +0.001 pp | USD7.36 +40.6% | 3 qtrs — |
| 37 | UBS GROUP AG | 271.7K +83.6K (+44.4%) | 2.81M +1.7M (+152.0%) | 0.46% +0.142 pp | 0.00% +0.000 pp | USD11.07 -6.5% | 20 qtrs — |
| 38 | ORBIMED ADVISORS LLC | 270.0K -1.7M (-86.0%) | 2.79M -8.6M (-75.5%) | 0.46% -2.802 pp | 0.06% -0.212 pp | USD20.88 -50.4% | 20 qtrs — |
| 39 | BARCLAYS PLC | 269.7K +21.0K (+8.5%) | 2.79M -1.4M (-32.9%) | 0.46% +0.036 pp | 0.00% 0.000 pp | USD14.46 -28.4% | 16 qtrs — |
| 40 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 244.0K +105.0K (+75.5%) | 2.53M +1.7M (+206.4%) | 0.41% +0.178 pp | 0.01% +0.004 pp | USD8.65 +19.7% | 5 qtrs — |
| 41 | CITIGROUP INC | 240.5K +133.3K (+124.4%) | 2.49M +1.9M (+291.6%) | 0.41% +0.226 pp | 0.00% +0.001 pp | USD9.30 +11.3% | 20 qtrs — |
| 42 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 233.8K +109.3K (+87.8%) | 2.42M +1.7M (+227.7%) | 0.40% +0.185 pp | 0.04% +0.026 pp | USD8.00 +29.4% | 2 qtrs — |
| 43 | PFM HEALTH SCIENCES, LP | 227.0K +227.0K (+100.0%) | 2.35M +2.3M (+100.0%) | 0.38% +0.385 pp | 0.23% +0.234 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 44 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 206.4K +195.7K (+1,829.0%) | 2.14M +2.1M (+3,266.8%) | 0.35% +0.332 pp | 0.00% +0.000 pp | USD10.59 -2.3% | 7 qtrs — |
| 45 | JANE STREET GROUP, LLC | 186.8K -114.0K (-37.9%) | 1.93M +149.6K (+8.4%) | 0.32% -0.193 pp | 0.00% +0.000 pp | USD6.60 +56.8% | 12 qtrs — |
| 46 | ALGERT GLOBAL LLC | 162.5K -73.6K (-31.2%) | 1.68M +282.0K (+20.1%) | 0.28% -0.125 pp | 0.03% +0.003 pp | USD8.48 +22.1% | 10 qtrs — |
| 47 | WELLINGTON MANAGEMENT GROUP LLP | 159.8K -8.4K (-5.0%) | 1.65M +656.4K (+65.8%) | 0.27% -0.014 pp | 0.00% +0.000 pp | USD13.79 -24.9% | 8 qtrs — |
| 48 | ASSENAGON ASSET MANAGEMENT S.A. | 158.8K -18.9K (-10.7%) | 1.64M +589.4K (+55.9%) | 0.27% -0.032 pp | 0.00% +0.001 pp | USD6.54 +58.3% | 7 qtrs — |
| 49 | JPMORGAN CHASE & CO | 147.1K +115.2K (+361.5%) | 1.52M +1.3M (+705.4%) | 0.25% +0.195 pp | 0.00% +0.000 pp | USD10.29 +0.6% | 20 qtrs — |
| 50 | BANK OF NEW YORK MELLON CORP | 144.9K -5.0K (-3.3%) | 1.50M +610.9K (+68.7%) | 0.25% -0.009 pp | 0.00% +0.000 pp | USD19.95 -48.1% | 20 qtrs — |
| 51 | AMERICAN CENTURY COMPANIES INC | 142.8K +1.7K (+1.2%) | 1.48M +641.0K (+76.6%) | 0.24% +0.003 pp | 0.00% +0.000 pp | USD12.01 -13.8% | 14 qtrs — |
| 52 | INVESCO LTD. | 130.3K +28.0K (+27.4%) | 1.35M +742.1K (+122.3%) | 0.22% +0.048 pp | 0.00% +0.000 pp | USD10.83 -4.4% | 9 qtrs — |
| 53 | TWO SIGMA ADVISERS, LP | 129.8K +92.5K (+248.0%) | 1.34M +1.1M (+507.4%) | 0.22% +0.157 pp | 0.00% +0.002 pp | USD9.08 +14.0% | 9 qtrs — |
| 54 | XTX TOPCO LTD | 121.3K -46.7K (-27.8%) | 1.26M +258.9K (+26.0%) | 0.21% -0.079 pp | 0.03% -0.019 pp | USD7.50 +38.0% | 5 qtrs — |
| 55 | QUBE RESEARCH & TECHNOLOGIES LTD | 119.3K -33.1K (-21.7%) | 1.23M +330.9K (+36.6%) | 0.20% -0.056 pp | 0.00% +0.000 pp | USD6.63 +56.1% | 9 qtrs — |
| 56 | CITADEL ADVISORS LLC | 110.3K -1.9M (-94.4%) | 1.14M -10.6M (-90.3%) | 0.19% -3.176 pp | 0.00% -0.002 pp | USD13.23 -21.8% | 20 qtrs — |
| 57 | HRT FINANCIAL LP | 84.1K +42.0K (+99.6%) | 870.0K +621.0K (+249.4%) | 0.14% +0.071 pp | 0.00% +0.002 pp | USD8.14 +27.1% | 4 qtrs — |
| 58 | SQUAREPOINT OPS LLC | 75.8K -14.5K (-16.1%) | 784.7K +249.2K (+46.5%) | 0.13% -0.025 pp | 0.00% +0.000 pp | USD6.20 +66.9% | 9 qtrs — |
| 59 | JACOBS LEVY EQUITY MANAGEMENT, INC | 73.8K +73.8K (+100.0%) | 763.4K +763.4K (+100.0%) | 0.13% +0.125 pp | 0.00% +0.003 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 60 | ENGINEERS GATE MANAGER LP | 69.3K +19.0K (+37.7%) | 717.7K +419.0K (+140.3%) | 0.12% +0.032 pp | 0.01% +0.005 pp | USD7.56 +36.9% | 3 qtrs — |
| 61 | RHUMBLINE ADVISERS | 67.2K -4.6K (-6.4%) | 695.9K +270.1K (+63.4%) | 0.11% -0.008 pp | 0.00% +0.000 pp | USD19.35 -46.5% | 20 qtrs — |
| 62 | RAFFERTY ASSET MANAGEMENT, LLC | 61.7K +20.9K (+51.4%) | 638.3K +396.8K (+164.3%) | 0.10% +0.036 pp | 0.00% +0.001 pp | USD14.80 -30.1% | 8 qtrs — |
| 63 | WELLS FARGO & COMPANY/MN | 60.5K +21.4K (+54.7%) | 626.3K +394.4K (+170.0%) | 0.10% +0.036 pp | 0.00% +0.000 pp | USD10.71 -3.4% | 20 qtrs — |
| 64 | SWISS NATIONAL BANK | 58.3K +8.0K (+15.9%) | 603.4K +305.1K (+102.3%) | 0.10% +0.014 pp | 0.00% +0.000 pp | USD16.60 -37.7% | 19 qtrs — |
| 65 | ADAR1 CAPITAL MANAGEMENT, LLC | 50.0K +50.0K (+100.0%) | 517.5K +517.5K (+100.0%) | 0.08% +0.085 pp | 0.04% +0.038 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 66 | VOLEON CAPITAL MANAGEMENT LP | 49.7K +49.7K (+100.0%) | 514.0K +514.0K (+100.0%) | 0.08% +0.084 pp | 0.01% +0.011 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 67 | MARINER, LLC | 49.1K +21.0K (+74.5%) | 508.2K +341.3K (+204.4%) | 0.08% +0.036 pp | 0.00% +0.000 pp | USD10.01 +3.4% | 7 qtrs — |
| 68 | UBS ASSET MANAGEMENT AMERICAS INC | 48.1K +888.0 (+1.9%) | 497.3K +217.7K (+77.8%) | 0.08% +0.002 pp | 0.00% +0.000 pp | USD13.62 -24.0% | 7 qtrs — |
| 69 | QUANTINNO CAPITAL MANAGEMENT LP | 48.0K -1.5K (-3.1%) | 496.8K +203.1K (+69.2%) | 0.08% -0.003 pp | 0.00% +0.000 pp | USD5.93 +74.5% | 2 qtrs — |
| 70 | ALLIANCEBERNSTEIN L.P. | 47.6K +— (+0.0%) | 493.0K +210.5K (+74.5%) | 0.08% +0.000 pp | 0.00% +0.000 pp | USD16.36 -36.7% | 19 qtrs — |
| 71 | KENNEDY CAPITAL MANAGEMENT LLC | 47.3K +1.3K (+2.7%) | 489.2K +216.4K (+79.3%) | 0.08% +0.002 pp | 0.01% +0.004 pp | USD7.60 +36.2% | 5 qtrs — |
| 72 | PRICE T ROWE ASSOCIATES INC /MD/ | 47.2K +4.0K (+9.1%) | 489.0K +232.0K (+90.3%) | 0.08% +0.007 pp | 0.00% +0.000 pp | USD11.35 -8.8% | 17 qtrs — |
| 73 | CREATIVE PLANNING | 39.9K +12.5K (+45.7%) | 412.9K +250.5K (+154.3%) | 0.07% +0.021 pp | 0.00% +0.000 pp | USD8.42 +22.9% | 4 qtrs — |
| 74 | BNP PARIBAS ARBITRAGE, SNC | 39.5K +28.8K (+269.7%) | 408.3K +345.0K (+545.3%) | 0.07% +0.049 pp | 0.00% +0.000 pp | USD10.70 -3.3% | 5 qtrs — |
| 75 | NEOS INVESTMENT MANAGEMENT LLC | 37.5K +37.5K (+100.0%) | 388.3K +388.3K (+100.0%) | 0.06% +0.064 pp | 0.00% +0.002 pp | USD10.35 +0.0% | 9 qtrs — |
| 76 | TEMA ETFS LLC | 37.0K +37.0K (+100.0%) | 382.6K +382.6K (+100.0%) | 0.06% +0.063 pp | 0.03% +0.030 pp | USD10.35 +0.0% | 5 qtrs — |
| 77 | AQUATIC CAPITAL MANAGEMENT LLC | 30.9K +28.1K (+1,011.5%) | 320.1K +303.6K (+1,840.1%) | 0.05% +0.048 pp | 0.01% +0.009 pp | USD9.95 +4.0% | 5 qtrs — |
| 78 | METLIFE INVESTMENT MANAGEMENT, LLC | 30.8K +7.6K (+32.6%) | 318.9K +181.1K (+131.4%) | 0.05% +0.013 pp | 0.00% +0.001 pp | USD16.84 -38.5% | 20 qtrs — |
| 79 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 30.8K -454.0 (-1.5%) | 318.8K +133.4K (+72.0%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD24.64 -58.0% | 20 qtrs — |
| 80 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 30.5K +30.5K (+100.0%) | 315.5K +315.5K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.003 pp | USD10.35 +0.0% | 5 qtrs — |
| 81 | QUEST PARTNERS LLC | 29.0K -69.0 (-0.2%) | 299.6K +127.6K (+74.1%) | 0.05% 0.000 pp | 0.02% +0.006 pp | USD6.52 +58.7% | 9 qtrs — |
| 82 | LEGAL & GENERAL GROUP PLC | 28.6K +13.3K (+87.2%) | 296.3K +205.6K (+226.7%) | 0.05% +0.023 pp | 0.00% +0.000 pp | USD13.75 -24.7% | 20 qtrs — |
| 83 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 28.7K +2.7K (+10.3%) | 295.1K +140.9K (+91.4%) | 0.05% +0.005 pp | 0.00% +0.000 pp | USD16.03 -35.4% | 7 qtrs — |
| 84 | INTECH INVESTMENT MANAGEMENT LLC | 27.9K +32.0 (+0.1%) | 289.1K +123.7K (+74.7%) | 0.05% +0.000 pp | 0.00% +0.001 pp | USD12.10 -14.5% | 6 qtrs — |
| 85 | GSA CAPITAL PARTNERS LLP | 27.3K +27.3K (+100.0%) | 283.0K +283.0K (+100.0%) | 0.05% +0.046 pp | 0.02% +0.024 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 86 | RUSSELL INVESTMENTS GROUP, LTD. | 24.4K +20.1K (+471.4%) | 252.6K +227.3K (+897.2%) | 0.04% +0.034 pp | 0.00% +0.000 pp | USD9.86 +5.0% | 4 qtrs — |
| 87 | ENTRYPOINT CAPITAL, LLC | 23.8K -18.4K (-43.6%) | 246.2K -4.0K (-1.6%) | 0.04% -0.031 pp | 0.10% -0.001 pp | USD7.10 +45.8% | 5 qtrs — |
| 88 | PROFUND ADVISORS LLC | 23.3K +23.3K (+100.0%) | 241.0K +241.0K (+100.0%) | 0.04% +0.040 pp | 0.01% +0.007 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 89 | VIRTUS INVESTMENT ADVISERS, INC. | 22.3K +9.6K (+75.5%) | 231.0K +155.6K (+206.4%) | 0.04% +0.016 pp | 0.06% +0.041 pp | USD8.60 +20.3% | 4 qtrs — |
| 90 | FOX RUN MANAGEMENT, L.L.C. | 21.2K +5.7K (+36.6%) | 219.5K +127.4K (+138.3%) | 0.04% +0.010 pp | 0.03% +0.020 pp | USD7.11 +45.6% | 2 qtrs — |
| 91 | BIRCHVIEW CAPITAL, LP | 20.0K +— (+0.0%) | 207.0K +88.4K (+74.5%) | 0.03% +0.000 pp | 0.12% +0.032 pp | USD41.67 -75.2% | 20 qtrs — |
| 92 | PALE FIRE CAPITAL SE | 19.3K +4.7K (+32.2%) | 199.9K +113.3K (+130.7%) | 0.03% +0.008 pp | 0.01% +0.004 pp | USD7.01 +47.6% | 2 qtrs — |
| 93 | ALPHACENTRIC ADVISORS LLC | 19.0K +19.0K (+100.0%) | 197.1K +197.1K (+100.0%) | 0.03% +0.032 pp | 0.20% +0.196 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 94 | JANUS HENDERSON GROUP PLC | 18.5K +— (+0.0%) | 191.4K +81.6K (+74.3%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD16.73 -38.1% | 7 qtrs — |
| 95 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 16.8K -1.0K (-5.6%) | 174.1K +68.4K (+64.7%) | 0.03% -0.002 pp | 0.00% +0.000 pp | USD22.66 -54.3% | 20 qtrs — |
| 96 | SCHONFELD STRATEGIC ADVISORS LLC | 16.6K +16.6K (+100.0%) | 172.2K +172.2K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.001 pp | USD10.35 +0.0% | 1 qtrs NEW |
| 97 | SG AMERICAS SECURITIES, LLC | 15.6K +5.2K (+49.4%) | 162.0K +100.0K (+161.3%) | 0.03% +0.009 pp | 0.00% +0.000 pp | USD7.39 +40.1% | 18 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 102 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree BioRevolution UCITS ETF - USD Acc WDNA.L | 0.98% | 218.1K | 0.45% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.81% | 468.9K | 0.65% |
| 3 | Tema Oncology ETF CANC | 0.59% | 842.2K | 0.75% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 0.40% | 143.9K | 0.45% |
| 5 | State Street SPDR S&P Biotech ETF XBI | 0.40% | 43.22M | 0.35% |
| 6 | iShares Micro-Cap ETF IWC | 0.25% | 3.67M | 0.60% |
| 7 | Vanguard U.S. Momentum Factor ETF VFMO | 0.11% | 1.89M | 0.13% |
| 8 | T. Rowe Price Small-Mid Cap ETF TMSL | 0.11% | 2.92M | 0.55% |
| 9 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.10% | 273.2K | 0.39% |
| 10 | Pacer WealthShield ETF PWS | 0.08% | 20.0K | 0.60% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.33
Bearish
Ratio by volume
0.33
Bearish
Buys
1
Sells
3
Shares acquired
4.0K
Shares disposed
12.0K
Cash buys
—
Cash sales
2.00
Net activity
-8,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Michaelson Jennifer | Officer | M-Exempt | A | Common Stock | 4,000 | 4.30 | 17.2K | 174,844 | D | ↗ |
| 2026-03-05 | Michaelson Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,000 | 4.30 | 17.2K | 120,987 | D | ↗ |
| 2026-02-25 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 1,780 | 14.14 | 25.2K | 174,844 | D | ↗ |
| 2026-02-24 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 3,601 | 14.47 | 52.1K | 128,089 | D | ↗ |
| 2026-02-24 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 3,601 | 14.47 | 52.1K | 176,624 | D | ↗ |
| 2026-02-24 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 4,582 | 14.47 | 66.3K | 159,968 | D | ↗ |
| 2026-02-24 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 13,515 | 14.47 | 195.6K | 390,803 | D | ↗ |
| 2026-02-23 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 1,752 | 13.99 | 24.5K | 180,225 | D | ↗ |
| 2026-02-20 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 3,742 | 13.62 | 51.0K | 131,690 | D | ↗ |
| 2026-02-20 | Michaelson Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,000 | 4.30 | 34.4K | 124,987 | D | ↗ |
| 2026-02-20 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 4,982 | 13.62 | 67.9K | 164,550 | D | ↗ |
| 2026-02-20 | Fenton Mary Kay | Officer | S-Sale | D | Common Stock | 4,398 | 13.62 | 59.9K | 126,380 | D | ↗ |
| 2026-02-20 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 16,381 | 13.62 | 223.1K | 404,318 | D | ↗ |
| 2026-02-18 | Savill Corrine | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 12.44 | 2.18M | 175,000 | D | ↗ |
| 2026-02-18 | SUMER JACQUELYN L | Officer | A-Award | A | Stock Option (Right to Buy) | 230,000 | 12.44 | 2.86M | 230,000 | D | ↗ |
| 2026-02-18 | Michaelson Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 12.44 | 1.43M | 115,000 | D | ↗ |
| 2026-02-18 | Jones Jeffrey Alan | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 12.44 | 3.73M | 300,000 | D | ↗ |
| 2026-02-18 | Fenton Mary Kay | Officer | A-Award | A | Stock Option (Right to Buy) | 137,500 | 12.44 | 1.71M | 137,500 | D | ↗ |
| 2026-02-18 | AHMED NADIM | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 828,000 | 12.44 | 10.30M | 828,000 | D | ↗ |
| 2026-02-12 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 416 | 12.03 | 5.0K | 128,219 | D | ↗ |
| 2026-01-22 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 4,000 | 12.30 | 49.2K | 128,635 | D | ↗ |
| 2025-12-31 | Fenton Mary Kay | Officer | A-Award | A | Common Stock | 27 | 6.49 | 175.23 | 62,028 | D | ↗ |
| 2025-12-23 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 9,922 | 10.01 | 99.3K | 420,699 | D | ↗ |
| 2025-12-19 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 1,345 | 10.01 | 13.5K | 132,635 | D | ↗ |
| 2025-12-18 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 3,480 | 9.67 | 33.7K | 135,432 | D | ↗ |
| 2025-12-18 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 2,898 | 9.67 | 28.0K | 133,980 | D | ↗ |
| 2025-12-18 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 4,632 | 9.67 | 44.8K | 169,532 | D | ↗ |
| 2025-12-15 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 995 | 11.90 | 11.8K | 136,878 | D | ↗ |
| 2025-12-12 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 2,148 | 12.38 | 26.6K | 137,873 | D | ↗ |
| 2025-11-24 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 4,000 | 12.30 | 49.2K | 138,004 | D | ↗ |
| 2025-10-28 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share | 165,667 | 8.40 | 1.39M | 8,963,500 | I | ↗ |
| 2025-10-17 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 32,217 | 7.84 | 252.6K | 8,797,833 | I | ↗ |
| 2025-10-16 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 8.86 | 1.33M | 8,765,616 | I | ↗ |
| 2025-10-15 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 51,500 | 7.94 | 409.0K | 8,615,616 | I | ↗ |
| 2025-10-14 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share ("Common Stock") | 15,032 | 7.59 | 114.0K | 8,564,116 | I | ↗ |
| 2025-10-10 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 277,298 | 7.36 | 2.04M | 8,549,084 | I | ↗ |
| 2025-10-09 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 626,043 | 6.70 | 4.19M | 8,271,786 | I | ↗ |
| 2025-10-08 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share ("Common Stock") | 556,300 | 6.46 | 3.59M | 7,645,743 | I | ↗ |
| 2025-08-07 | Doyle Mittie | Director | A-Award | A | Stock Option (Right to Buy) | 79,456 | 7.03 | 558.6K | 79,456 | D | ↗ |
| 2025-08-07 | Allen Andrew R | Director | A-Award | A | Stock Option (Right to Buy) | 79,456 | 7.03 | 558.6K | 79,456 | D | ↗ |
| 2025-06-12 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 38,513 | 8.95 | 344.7K | 38,513 | D | ↗ |
| 2025-06-12 | Ryan David P. | Director | A-Award | A | Stock Option (Right to Buy) | 38,513 | 8.95 | 344.7K | 38,513 | D | ↗ |
| 2025-06-12 | Rosenberg Anthony | Director | A-Award | A | Stock Option (Right to Buy) | 38,513 | 8.95 | 344.7K | 38,513 | D | ↗ |
| 2025-06-12 | Meek David D. | Director | A-Award | A | Stock Option (Right to Buy) | 38,513 | 8.95 | 344.7K | 38,513 | D | ↗ |
| 2025-06-12 | Martin Anne-Marie | Director | A-Award | A | Stock Option (Right to Buy) | 38,513 | 8.95 | 344.7K | 38,513 | D | ↗ |
| 2025-02-25 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 3,756 | 8.53 | 32.0K | 136,895 | D | ↗ |
| 2025-02-25 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 3,756 | 8.53 | 32.0K | 142,004 | D | ↗ |
| 2025-02-25 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 4,895 | 8.53 | 41.8K | 174,164 | D | ↗ |
| 2025-02-25 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 12,529 | 8.53 | 106.9K | 430,621 | D | ↗ |
| 2025-02-19 | Savill Corrine | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 9.43 | 707.3K | 75,000 | D | ↗ |
| 2025-02-19 | SUMER JACQUELYN L | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 9.43 | 943.0K | 100,000 | D | ↗ |
| 2025-02-19 | Michaelson Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 9.43 | 943.0K | 100,000 | D | ↗ |
| 2025-02-19 | Jones Jeffrey Alan | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 9.43 | 1.23M | 130,000 | D | ↗ |
| 2025-02-19 | Fenton Mary Kay | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 9.43 | 1.13M | 120,000 | D | ↗ |
| 2025-02-19 | AHMED NADIM | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 360,000 | 9.43 | 3.39M | 360,000 | D | ↗ |
| 2025-01-06 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 4,000 | 12.51 | 50.0K | 95,760 | D | ↗ |
| 2024-12-24 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 8,400 | 11.87 | 99.7K | 263,150 | D | ↗ |
| 2024-12-18 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 3,482 | 11.41 | 39.7K | 90,651 | D | ↗ |
| 2024-12-18 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 4,693 | 11.41 | 53.5K | 99,760 | D | ↗ |
| 2024-12-18 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 4,632 | 11.41 | 52.9K | 114,059 | D | ↗ |
| 2024-12-12 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 3,489 | 12.52 | 43.7K | 104,453 | D | ↗ |
| 2024-11-05 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 8,000 | 15.64 | 125.1K | 107,942 | D | ↗ |
| 2024-09-05 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 8,000 | 18.09 | 144.7K | 115,942 | — | ↗ |
| 2024-08-08 | Thistle Mary | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-05 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 8,000 | 16.33 | 130.6K | 123,942 | — | ↗ |
| 2024-07-01 | Michaelson Jennifer | Officer | A-Award | A | Common Stock | 2,360 | 9.00 | 21.2K | 131,942 | — | ↗ |
| 2024-06-26 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 15,806 | 16.50 | 260.8K | 15,806 | — | ↗ |
| 2024-06-26 | Ryan David P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,806 | 16.50 | 260.8K | 15,806 | — | ↗ |
| 2024-06-26 | Rosenberg Anthony | Director | A-Award | A | Stock Option (Right to Buy) | 15,806 | 16.50 | 260.8K | 15,806 | — | ↗ |
| 2024-06-26 | Martin Anne-Marie | Director | A-Award | A | Stock Option (Right to Buy) | 15,806 | 16.50 | 260.8K | 15,806 | — | ↗ |
| 2024-06-10 | Ebeling Thomas | Director | M-Exempt | A | Common Stock | 18,450 | 13.00 | 239.9K | 186,653 | — | ↗ |
| 2024-05-23 | Ebeling Thomas | Director | A-Award | A | Common Stock | 16,475 | 12.73 | 209.7K | 168,203 | — | ↗ |
| 2024-05-15 | Meek David D. | Director | A-Award | A | Stock Option (Right to Buy) | 15,618 | 26.72 | 417.3K | 15,618 | — | ↗ |
| 2024-05-07 | Michaelson Jennifer | Officer | M-Exempt | A | Common Stock | 5,606 | 4.30 | 24.1K | 135,188 | — | ↗ |
| 2024-05-06 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 20,277 | 28.54 | 578.7K | 129,582 | — | ↗ |
| 2024-04-29 | Fenton Mary Kay | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 27.12 | 5.42M | 200,000 | — | ↗ |
| 2024-03-29 | Nguyen Nate | Officer | — | D | Stock Option (Right to Buy) | 26,750 | 17.54 | 469.2K | 0 | — | ↗ |
| 2024-02-22 | Trigilio Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 17.54 | 1.75M | 100,000 | — | ↗ |
| 2024-02-22 | Savill Corrine | Officer | A-Award | A | Common Stock | 37,500 | 0.00 | — | 203,490 | — | ↗ |
| 2024-02-22 | SUMER JACQUELYN L | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 94,133 | — | ↗ |
| 2024-02-22 | Michaelson Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 17.54 | 1.75M | 100,000 | — | ↗ |
| 2024-02-22 | Jones Jeffrey Alan | Officer | A-Award | A | Common Stock | 62,500 | 0.00 | — | 118,691 | — | ↗ |
| 2024-02-22 | AHMED NADIM | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 320,000 | 17.54 | 5.61M | 320,000 | — | ↗ |
| 2024-02-01 | Savill Corrine | Officer | M-Exempt | A | Common Stock | 40,000 | 4.30 | 172.0K | 205,990 | — | ↗ |
| 2024-01-29 | Savill Corrine | Officer | M-Exempt | A | Common Stock | 40,000 | 4.30 | 172.0K | 205,990 | — | ↗ |
| 2024-01-23 | Savill Corrine | Officer | S-Sale | D | Common Stock | 21,316 | 12.46 | 265.6K | 165,990 | — | ↗ |
| 2024-01-22 | Savill Corrine | Officer | S-Sale | D | Common Stock | 4,125 | 12.02 | 49.6K | 165,990 | — | ↗ |
| 2023-12-26 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 4,272 | 9.24 | 39.5K | 111,550 | — | ↗ |
| 2023-12-21 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 1,920 | 8.50 | 16.3K | 83,919 | — | ↗ |
| 2023-12-21 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 1,400 | 8.50 | 11.9K | 44,133 | — | ↗ |
| 2023-12-21 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 1,145 | 8.50 | 9.7K | 87,582 | — | ↗ |
| 2023-12-21 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 1,860 | 8.50 | 15.8K | 56,191 | — | ↗ |
| 2023-12-18 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 398 | 8.22 | 3.3K | 85,839 | — | ↗ |
| 2023-12-18 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 290 | 8.22 | 2.4K | 45,533 | — | ↗ |
| 2023-12-18 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 238 | 8.22 | 2.0K | 88,727 | — | ↗ |
| 2023-12-18 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 386 | 8.22 | 3.2K | 58,051 | — | ↗ |
| 2023-12-12 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 1,926 | 7.81 | 15.0K | 86,237 | — | ↗ |
| 2023-12-12 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 1,068 | 7.81 | 8.3K | 88,965 | — | ↗ |
| 2023-06-30 | Trigilio Jeffrey | Officer | A-Award | A | Common Stock | 2,340 | 9.08 | 21.2K | 88,163 | — | ↗ |
| 2023-06-28 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 759 | 11.40 | 8.7K | 115,822 | — | ↗ |
| 2023-06-20 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 399 | 12.94 | 5.2K | 85,823 | — | ↗ |
| 2023-06-20 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 291 | 12.94 | 3.8K | 45,823 | — | ↗ |
| 2023-06-20 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 238 | 12.94 | 3.1K | 90,033 | — | ↗ |
| 2023-06-20 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 387 | 12.94 | 5.0K | 58,437 | — | ↗ |
| 2023-06-12 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 319 | 13.11 | 4.2K | 86,222 | — | ↗ |
| 2023-06-12 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 176 | 13.11 | 2.3K | 90,271 | — | ↗ |
| 2023-06-08 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 18,450 | 13.00 | 239.9K | 18,450 | — | ↗ |
| 2023-06-08 | Rosenberg Anthony | Director | A-Award | A | Stock Option (Right to Buy) | 18,450 | 13.00 | 239.9K | 18,450 | — | ↗ |
| 2023-06-08 | Martin Anne-Marie | Director | A-Award | A | Stock Option (Right to Buy) | 18,450 | 13.00 | 239.9K | 18,450 | — | ↗ |
| 2023-06-08 | Ebeling Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 18,450 | 13.00 | 239.9K | 18,450 | — | ↗ |
| 2023-06-07 | Michaelson Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 100 | 4.30 | 430.00 | 188,593 | — | ↗ |
| 2023-06-06 | Michaelson Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,900 | 4.30 | 51.2K | 188,693 | — | ↗ |
| 2023-05-23 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 707 | 9.15 | 6.5K | 116,581 | — | ↗ |
| 2023-05-18 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 399 | 8.76 | 3.5K | 86,541 | — | ↗ |
| 2023-05-18 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 291 | 8.76 | 2.5K | 46,114 | — | ↗ |
| 2023-05-18 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 239 | 8.76 | 2.1K | 90,447 | — | ↗ |
| 2023-05-18 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 394 | 8.76 | 3.5K | 58,824 | — | ↗ |
| 2023-05-12 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 347 | 8.78 | 3.0K | 86,940 | — | ↗ |
| 2023-05-12 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 193 | 8.78 | 1.7K | 90,686 | — | ↗ |
| 2023-04-25 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 716 | 10.59 | 7.6K | 117,288 | — | ↗ |
| 2023-04-18 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 398 | 10.71 | 4.3K | 87,287 | — | ↗ |
| 2023-04-18 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 290 | 10.71 | 3.1K | 46,405 | — | ↗ |
| 2023-04-18 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 238 | 10.71 | 2.5K | 90,879 | — | ↗ |
| 2023-04-18 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 392 | 10.71 | 4.2K | 59,218 | — | ↗ |
| 2023-04-12 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 318 | 10.22 | 3.2K | 87,685 | — | ↗ |
| 2023-04-12 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 176 | 10.22 | 1.8K | 91,117 | — | ↗ |
| 2023-03-23 | AHMED NADIM | Director / Officer | S-Sale | D | Common Stock | 706 | 10.51 | 7.4K | 118,004 | — | ↗ |
| 2023-03-20 | Trigilio Jeffrey | Officer | S-Sale | D | Common Stock | 399 | 11.32 | 4.5K | 88,003 | — | ↗ |
| 2023-03-20 | SUMER JACQUELYN L | Officer | S-Sale | D | Common Stock | 305 | 11.32 | 3.5K | 46,695 | — | ↗ |
| 2023-03-20 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 238 | 11.32 | 2.7K | 91,293 | — | ↗ |
| 2023-03-20 | Jones Jeffrey Alan | Officer | S-Sale | D | Common Stock | 390 | 11.32 | 4.4K | 59,610 | — | ↗ |
| 2023-02-22 | AHMED NADIM | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 211,000 | 11.03 | 2.33M | 211,000 | — | ↗ |
| 2023-02-17 | Trigilio Jeffrey | Officer | A-Award | A | Common Stock | 47,000 | 0.00 | — | 88,402 | — | ↗ |
| 2023-02-17 | Savill Corrine | Officer | A-Award | A | Common Stock | 20,500 | 0.00 | — | 170,115 | — | ↗ |
| 2023-02-17 | SUMER JACQUELYN L | Officer | A-Award | A | Common Stock | 47,000 | 0.00 | — | 47,000 | — | ↗ |
| 2023-02-17 | Michaelson Jennifer | Officer | A-Award | A | Common Stock | 38,500 | 0.00 | — | 91,531 | — | ↗ |
| 2023-02-17 | Jones Jeffrey Alan | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2023-02-17 | Baeuerle Patrick | Officer | A-Award | A | Common Stock | 38,500 | 0.00 | — | 76,000 | — | ↗ |
| 2023-01-19 | BVF PARTNERS L P/IL | Director | J-Other | D | Common Stock | 3,500,000 | 0.00 | — | 558,854 | — | ↗ |
| 2022-12-30 | Trigilio Jeffrey | Officer | A-Award | A | Common Stock | 201 | 8.97 | 1.8K | 41,402 | — | ↗ |
| 2022-11-25 | Michaelson Jennifer | Officer | M-Exempt | A | Common Stock | 4,000 | 4.30 | 17.2K | 57,031 | — | ↗ |
| 2022-11-01 | Ryan David P. | Director | A-Award | A | Stock Option (Right to Buy) | 26,150 | 0.00 | — | 26,150 | — | ↗ |
| 2022-08-15 | SUMER JACQUELYN L | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 0.00 | — | 190,000 | — | ↗ |
| 2022-08-08 | Michaelson Jennifer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,385 | 0.00 | — | 208,593 | — | ↗ |
| 2022-08-04 | F2 Vision SCS | 10% Owner | S-Sale | D | Common Stock | 25,989 | 14.31 | 371.8K | 1,255,963 | — | ↗ |
| 2022-08-03 | F2 Vision SCS | 10% Owner | S-Sale | D | Common Stock | 19,129 | 14.24 | 272.3K | 1,281,952 | — | ↗ |
| 2022-08-02 | Jovan-Embiricos Morana | Director | S-Sale | D | Common Stock | 19,129 | 14.24 | 272.3K | 1,281,952 | — | ↗ |
| 2022-08-02 | F2 Vision SCS | 10% Owner | S-Sale | D | Common Stock | 4,792 | 14.10 | 67.6K | 1,301,081 | — | ↗ |
| 2022-07-25 | Michaelson Jennifer | Officer | M-Exempt | A | Common Stock | 8,000 | 4.30 | 34.4K | 61,031 | — | ↗ |
| 2022-07-18 | Savill Corrine | Officer | S-Sale | D | Common Stock | 14,958 | 15.22 | 227.7K | 149,615 | — | ↗ |
| 2022-07-11 | Savill Corrine | Officer | S-Sale | D | Common Stock | 200 | 13.85 | 2.8K | 169,615 | — | ↗ |
| 2022-06-30 | Trigilio Jeffrey | Officer | A-Award | A | Common Stock | 1,451 | 10.90 | 15.8K | 41,201 | — | ↗ |
| 2022-06-30 | Michaelson Jennifer | Officer | A-Award | A | Common Stock | 1,620 | 10.90 | 17.7K | 53,031 | — | ↗ |
| 2022-06-30 | AHMED NADIM | Officer | A-Award | A | Common Stock | 1,620 | 10.90 | 17.7K | 9,710 | — | ↗ |
| 2022-06-24 | Jovan-Embiricos Morana | 10% Owner | M-Exempt | A | Common Stock | 35,529 | 4.30 | 152.8K | 252,881 | — | ↗ |
| 2022-06-23 | F2 Bioscience I 2017 Ltd | 10% Owner | S-Sale | D | Common Stock | 29,631 | 13.00 | 385.3K | 537,392 | — | ↗ |
| 2022-06-22 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 16,475 | 0.00 | — | 16,475 | — | ↗ |
| 2022-06-22 | Rosenberg Anthony | Director | A-Award | A | Stock Option (Right to Buy) | 16,475 | 0.00 | — | 16,475 | — | ↗ |
| 2022-06-22 | GADICKE ANSBERT | Director | A-Award | A | Stock Option (Right to Buy) | 16,475 | 12.73 | 209.7K | 16,475 | — | ↗ |
| 2022-06-22 | F2 Bioscience I 2017 Ltd | 10% Owner | S-Sale | D | Common Stock | 49,953 | 12.70 | 634.6K | 567,023 | — | ↗ |
| 2022-06-22 | Ebeling Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 16,475 | 0.00 | — | 16,475 | — | ↗ |
| 2022-06-21 | Jovan-Embiricos Morana | Director | S-Sale | D | Common Stock | 49,953 | 12.70 | 634.6K | 567,023 | — | ↗ |
| 2022-06-21 | F2 Bioscience I 2017 Ltd | 10% Owner | S-Sale | D | Common Stock | 22,319 | 12.77 | 284.9K | 616,976 | — | ↗ |
| 2022-06-06 | AHMED NADIM | Officer | P-Purchase | A | Common Stock | 8,090 | 12.40 | 100.3K | 8,090 | — | ↗ |
| 2022-06-01 | LAMPERT MARK N | Director | P-Purchase | A | Common Stock | 405,641 | 11.00 | 4.46M | 4,058,854 | — | ↗ |
| 2022-05-16 | F2 Vision SCS | 10% Owner | S-Sale | D | Common Stock | 35,158 | 11.23 | 394.8K | 1,305,873 | — | ↗ |
| 2022-05-13 | F2 Vision SCS | 10% Owner | S-Sale | D | Common Stock | 85,319 | 9.96 | 850.0K | 1,375,220 | — | ↗ |
| 2022-05-12 | LAMPERT MARK N | Director | P-Purchase | A | Common Stock | 17,744 | 9.14 | 162.1K | 319,415 | — | ↗ |
| 2022-05-12 | Jovan-Embiricos Morana | Director | S-Sale | D | Common Stock | 34,189 | 10.48 | 358.3K | 1,341,031 | — | ↗ |
| 2022-05-12 | F2 Vision SCS | 10% Owner | S-Sale | D | Common Stock | 264,072 | 9.25 | 2.44M | 1,460,539 | — | ↗ |
| 2022-04-01 | LAMPERT MARK N | Director | P-Purchase | A | Common Stock | 9,402 | 10.75 | 101.1K | 2,196,240 | — | ↗ |
| 2022-03-05 | AHMED NADIM | Officer | A-Award | A | Performance Stock Unit | 215,000 | 0.00 | — | 215,000 | — | ↗ |
| 2022-03-01 | Martin Anne-Marie | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-28 | Jones Jeffrey Alan | Officer | A-Award | A | Stock Option (Right to Buy) | 215,000 | 14.34 | 3.08M | 215,000 | — | ↗ |
| 2022-02-11 | Zawel Leigh | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 13.60 | 884.0K | 65,000 | — | ↗ |
| 2022-02-11 | Trigilio Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 13.60 | 1.02M | 75,000 | — | ↗ |
| 2022-02-11 | Savill Corrine | Officer | A-Award | A | Common Stock | 16,500 | 0.00 | — | 209,615 | — | ↗ |
| 2022-02-11 | Michaelson Jennifer | Officer | A-Award | A | Common Stock | 28,500 | 0.00 | — | 51,411 | — | ↗ |
| 2022-02-11 | Keane Raymond T | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 24,124 | — | ↗ |
| 2022-02-11 | Baeuerle Patrick | Officer | A-Award | A | Common Stock | 37,500 | 0.00 | — | 37,500 | — | ↗ |
| 2022-01-11 | F2 Vision SCS | 10% Owner | J-Other | D | Common Stock | 1,187,734 | 0.00 | — | 1,724,611 | — | ↗ |
| 2021-12-31 | GADICKE ANSBERT | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 7,648,268 | — | ↗ |
| 2021-12-31 | BVF PARTNERS L P/IL | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,790,018 | — | ↗ |
| 2021-12-21 | GADICKE ANSBERT | 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 88,824 | 4.30 | 381.9K | 0 | — | ↗ |
| 2021-10-18 | Michaelson Jennifer | Officer | M-Exempt | A | Common Stock | 4,000 | 4.30 | 17.2K | 26,911 | — | ↗ |
| 2021-10-18 | AHMED NADIM | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-15 | Zawel Leigh | Officer | S-Sale | D | Common Stock | 19,574 | 25.00 | 489.4K | 37,285 | — | ↗ |
| 2021-10-15 | Trigilio Jeffrey | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,000 | 4.30 | 34.4K | 229,891 | — | ↗ |
| 2021-10-07 | Zawel Leigh | Officer | S-Sale | D | Common Stock | 1,079 | 25.00 | 27.0K | 56,859 | — | ↗ |
| 2021-09-20 | Zawel Leigh | Officer | S-Sale | D | Common Stock | 7,468 | 25.16 | 187.9K | 57,938 | — | ↗ |
| 2021-09-20 | Michaelson Jennifer | Officer | S-Sale | D | Common Stock | 3,200 | 24.34 | 77.9K | 23,711 | — | ↗ |
| 2021-09-16 | Webster Stephen W | Director | A-Award | A | Stock Option (Right to Buy) | 7,800 | 28.80 | 224.6K | 7,800 | — | ↗ |
| 2021-09-16 | UBS Oncology Impact Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 3,124 | 29.06 | 90.8K | 7,648,268 | — | ↗ |
| 2021-09-16 | Rosenberg Anthony | Director | A-Award | A | Stock Option (Right to Buy) | 7,800 | 28.80 | 224.6K | 7,800 | — | ↗ |
| 2021-09-16 | Jovan-Embiricos Morana | Director | A-Award | A | Stock Option (Right to Buy) | 7,800 | 28.80 | 224.6K | 7,800 | — | ↗ |
| 2021-09-16 | GADICKE ANSBERT | Director / 10% Owner | S-Sale | D | Common Stock | 432 | 29.06 | 12.6K | 244,551 | — | ↗ |
| 2021-09-16 | Ebeling Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 7,800 | 28.80 | 224.6K | 7,800 | — | ↗ |
| 2021-09-15 | UBS Oncology Impact Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 6,425 | 29.16 | 187.4K | 7,651,392 | — | ↗ |
| 2021-09-15 | GADICKE ANSBERT | Director / 10% Owner | S-Sale | D | Common Stock | 888 | 29.16 | 25.9K | 244,983 | — | ↗ |
| 2021-09-14 | UBS Oncology Impact Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 7,106 | 29.17 | 207.3K | 7,657,817 | — | ↗ |
Executive team
Top executives
Shares Outstanding
61.45M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Nadim Ahmed President and Chief Executive Officer | 698.5K | — | 1.70M | 2.23M | 419.1K | 50.7K | 5.10M | 77.09% | ↗ |
| 2 | 2025 | Jeffrey Jones, M.D. Chief Medical Officer | 529.8K | — | 613.0K | 806.8K | 218.3K | 53.7K | 2.22M | 63.91% | ↗ |
| 3 | 2025 | Mary Kay Fenton Chief Financial Officer | 512.3K | — | 565.8K | 744.8K | 211.9K | 44.0K | 2.08M | 63.04% | ↗ |
| 4 | 2024 | Nadim Ahmed President and Chief Executive Officer | 674.9K | — | 2.81M | 3.70M | 455.5K | 43.4K | 7.68M | 84.72% | ↗ |
| 5 | 2024 | Mary Kay Fenton Chief Financial Officer | 333.8K | — | — | 3.60M | 174.6K | 35.8K | 4.14M | 86.86% | ↗ |
| 6 | 2024 | Jeffrey Trigilio Former Chief Financial Officer | 123.4K | 49.4K | 1.50M | 1.77M | — | 561.2K | 4.00M | 81.66% | ↗ |
| 7 | 2024 | Jeffrey Jones, M.D. Chief Medical Officer | 511.9K | — | 1.10M | 1.45M | 274.4K | 58.6K | 3.39M | 75.06% | ↗ |
| 8 | 2023 | Nadim Ahmed President and Chief Executive Officer | 648.9K | 389.3K | 1.20M | 1.65M | — | 122.3K | 4.01M | 71.05% | ↗ |
| 9 | 2023 | Jeffrey Jones, M.D. Chief Medical Officer | 492.2K | 236.3K | 680.4K | 960.9K | — | 51.9K | 2.42M | 67.78% | ↗ |
| 10 | 2023 | Jeffrey Trigilio Former Chief Financial Officer | 474.6K | 404.8K | 533.0K | 748.7K | — | 43.2K | 2.20M | 58.15% | ↗ |
| 11 | 2022 | Nadim Ahmed President and Chief Executive Officer | 618.0K | 370.8K | 2.76M | — | — | 149.0K | 3.90M | 70.83% | ↗ |
| 12 | 2022 | Patrick Baeuerle, Ph.D. Chief Scientific Officer | 463.5K | 266.2K | 510.0K | 686.3K | — | 34.0K | 1.96M | 61.03% | ↗ |
| 13 | 2022 | Jeffrey Trigilio Former Chief Financial Officer | 452.0K | 260.4K | 510.0K | 686.3K | — | 15.6K | 1.92M | 62.17% | ↗ |
| 14 | 2022 | Jeffrey Trigilio Chief Financial Officer | 452.0K | 260.4K | 510.0K | 686.3K | — | 15.6K | 1.92M | 62.17% | ↗ |
| 15 | 2021 | Nadim Ahmed President and Chief Executive Officer | 125.0K | 699.0K | — | 37.72M | — | — | 38.55M | 97.86% | ↗ |
| 16 | 2021 | Nadim Ahmed, President and Chief Executive Officer | 125.0K | 699.0K | — | 37.72M | — | — | 38.55M | 97.86% | ↗ |
| 17 | 2021 | Owen Hughes, Former President and Chief Executive Officer | 433.3K | 216.5K | — | 6.01M | — | 130.4K | 6.79M | 88.50% | ↗ |
| 18 | 2021 | Patrick Baeuerle, Ph.D., Acting Chief Scientific Officer | 450.0K | 218.0K | — | 3.97M | — | 34.8K | 4.68M | 84.97% | ↗ |
| 19 | 2021 | Patrick Baeuerle, Ph.D. Chief Scientific Officer | 450.0K | 218.0K | — | 3.97M | — | 34.8K | 4.68M | 84.97% | ↗ |
| 20 | 2021 | Jeffrey Trigilio Chief Financial Officer | 400.0K | 220.0K | — | 2.03M | — | 14.9K | 2.67M | 76.20% | ↗ |
| 21 | 2021 | Jeffrey Trigilio, Chief Financial Officer | 400.0K | 220.0K | — | 2.03M | — | 14.5K | 2.67M | 76.21% | ↗ |
| 22 | 2020 | Owen Hughes Chief Executive Officer | 461.3K | 245.1K | 530.3K | 5.30M | — | 14.3K | 6.55M | 89.00% | ↗ |
| 23 | 2020 | Owen Hughes, Former President and Chief Executive Officer | 461.3K | 245.1K | 530.3K | 5.30M | — | 14.3K | 6.55M | 89.00% | ↗ |
| 24 | 2020 | Patrick Bauerle, Ph.D. Acting Chief Scientific Officer, Biologics | 437.0K | 266.1K | 491.3K | 4.12M | — | 34.8K | 5.35M | 86.22% | ↗ |
| 25 | 2020 | Patrick Baeuerle, Ph.D., Acting Chief Scientific Officer | 437.0K | 266.1K | 491.3K | 4.12M | — | 34.8K | 5.35M | 86.22% | ↗ |
| 26 | 2020 | Jon Wigginton, M.D. Chief Medical Officer | 321.1K | 258.0K | — | 3.96M | — | 5.4K | 4.54M | 87.14% | ↗ |
| 27 | 2020 | Jeffrey Trigilio, Chief Financial Officer | 118.0K | 53.2K | — | 1.57M | — | — | 1.74M | 90.15% | ↗ |
| 28 | 2019 | Patrick Bauerle, Ph.D. Acting Chief Scientific Officer, Biologics | 420.9K | 107.5K | — | — | — | 34.4K | 562.8K | 0.00% | ↗ |
| 29 | 2019 | Owen Hughes Chief Executive Officer | 450.0K | 96.8K | — | — | — | 14.0K | 560.8K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nadim Ahmed | President, Chief Executive Officer & Director | 1M | male |
| Jeffrey Jones | Chief Medical Officer | 801.8K | — |
| Mary Kay Fenton | Chief Financial Officer | 768.3K | female |
| Patrick A. Baeuerle | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | 763.7K | — |
| Nicholas Smith | Head of Investor Relations | — | — |
| Rose Weldon | Senior Vice President of Corporate Affairs | — | female |
| Corinne Savill | Chief Business Officer | — | — |
| Steve Andre | Chief Human Resources Officer | — | male |
| Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | — | female |
| Jennifer Michaelson | Chief Scientific Officer | — | — |
| Kevin A. Johnston | Chief Technical Operations Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CGEM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
